Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendroglioma

Alissa A. Thomas; Lauren E. Abrey; Robert Terziev; Jeffrey Raizer; Nina L. Martinez; Peter Forsyth; Nina Paleologos; Matthew Matasar; Craig S. Sauter; Craig Moskowitz; Stephen D. Nimer; Lisa M. Deangelis; Thomas Kaley; Sean Grimm; David N. Louis; J. Gregory Cairncross; Katherine S. Panageas; Samuel Briggs; Geraldine Faivre; Nimish A. Mohile; Jayesh Mehta; Philip Jonsson; Debyani Chakravarty; Jianjiong Gao; Nikolaus Schultz; Cameron W. Brennan; Jason T. Huse; Antonio Omuro

doi:10.1093/neuonc/nox086

Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendroglioma

Alissa A. Thomas, Lauren E. Abrey, Robert Terziev, Jeffrey Raizer, Nina L. Martinez, Peter Forsyth, Nina Paleologos, Matthew Matasar, Craig S. Sauter, Craig Moskowitz, Stephen D. Nimer, Lisa M. Deangelis, Thomas Kaley, Sean Grimm, David N. Louis, J. Gregory Cairncross, Katherine S. Panageas, Samuel Briggs, Geraldine Faivre, Nimish A. MohileJayesh Mehta, Philip Jonsson, Debyani Chakravarty, Jianjiong Gao, Nikolaus Schultz, Cameron W. Brennan, Jason T. Huse, Antonio Omuro^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

21 Scopus citations

Abstract

Background. Anaplastic oligodendroglioma (AO) and anaplastic oligoastrocytoma (AOA) are chemotherapy-sensitive tumors with prolonged survival after radiochemotherapy. We report a prospective trial using induction temozolomide (TMZ) followed by myeloablative high-dose chemotherapy (HDC) with autologous stem-cell transplant (ASCT) as a potential strategy to defer radiotherapy. Methods. Patients with AO/AOA received 6 cycles of TMZ (200 mg/m² × 5/28 day). Responding patients were eligible for HDC (thiotepa 250 mg/m²/day

Original language	English (US)
Pages (from-to)	1380-1390
Number of pages	11
Journal	Neuro-oncology
Volume	19
Issue number	10
DOIs	https://doi.org/10.1093/neuonc/nox086
State	Published - Oct 1 2017

Keywords

1p/19q codeletion
Anaplastic oligodendroglioma
Autologous stem cell transplant
Temozolomide

ASJC Scopus subject areas

Oncology
Clinical Neurology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/neuonc/nox086

Cite this

Thomas, A. A., Abrey, L. E., Terziev, R., Raizer, J., Martinez, N. L., Forsyth, P., Paleologos, N., Matasar, M., Sauter, C. S., Moskowitz, C., Nimer, S. D., Deangelis, L. M., Kaley, T., Grimm, S., Louis, D. N., Cairncross, J. G., Panageas, K. S., Briggs, S., Faivre, G., ... Omuro, A. (2017). Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendroglioma. Neuro-oncology, 19(10), 1380-1390. https://doi.org/10.1093/neuonc/nox086

@article{6be09b8ae34e49a686d5fff7a7c0d18a,

title = "Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendroglioma",

abstract = "Background. Anaplastic oligodendroglioma (AO) and anaplastic oligoastrocytoma (AOA) are chemotherapy-sensitive tumors with prolonged survival after radiochemotherapy. We report a prospective trial using induction temozolomide (TMZ) followed by myeloablative high-dose chemotherapy (HDC) with autologous stem-cell transplant (ASCT) as a potential strategy to defer radiotherapy. Methods. Patients with AO/AOA received 6 cycles of TMZ (200 mg/m2 × 5/28 day). Responding patients were eligible for HDC (thiotepa 250 mg/m2/day",

keywords = "1p/19q codeletion, Anaplastic oligodendroglioma, Autologous stem cell transplant, Temozolomide",

author = "Thomas, {Alissa A.} and Abrey, {Lauren E.} and Robert Terziev and Jeffrey Raizer and Martinez, {Nina L.} and Peter Forsyth and Nina Paleologos and Matthew Matasar and Sauter, {Craig S.} and Craig Moskowitz and Nimer, {Stephen D.} and Deangelis, {Lisa M.} and Thomas Kaley and Sean Grimm and Louis, {David N.} and Cairncross, {J. Gregory} and Panageas, {Katherine S.} and Samuel Briggs and Geraldine Faivre and Mohile, {Nimish A.} and Jayesh Mehta and Philip Jonsson and Debyani Chakravarty and Jianjiong Gao and Nikolaus Schultz and Brennan, {Cameron W.} and Huse, {Jason T.} and Antonio Omuro",

note = "Funding Information: This is an investigator-initiated prospective multicenter phase II trial sponsored by Memorial Sloan Kettering Cancer Center, supported in part by NIH grant P30 CA 008748. Schering-Plough/ Merck provided temozolomide and additional partial financial support. Publisher Copyright: {\textcopyright} 2017 The Author(s).",

year = "2017",

month = oct,

day = "1",

doi = "10.1093/neuonc/nox086",

language = "English (US)",

volume = "19",

pages = "1380--1390",

journal = "Neuro-Oncology",

issn = "1522-8517",

publisher = "Oxford University Press",

number = "10",

}

Thomas, AA, Abrey, LE, Terziev, R, Raizer, J, Martinez, NL, Forsyth, P, Paleologos, N, Matasar, M, Sauter, CS, Moskowitz, C, Nimer, SD, Deangelis, LM, Kaley, T, Grimm, S, Louis, DN, Cairncross, JG, Panageas, KS, Briggs, S, Faivre, G, Mohile, NA, Mehta, J, Jonsson, P, Chakravarty, D, Gao, J, Schultz, N, Brennan, CW, Huse, JT & Omuro, A 2017, 'Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendroglioma', Neuro-oncology, vol. 19, no. 10, pp. 1380-1390. https://doi.org/10.1093/neuonc/nox086

TY - JOUR

T1 - Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendroglioma

AU - Thomas, Alissa A.

AU - Abrey, Lauren E.

AU - Terziev, Robert

AU - Raizer, Jeffrey

AU - Martinez, Nina L.

AU - Forsyth, Peter

AU - Paleologos, Nina

AU - Matasar, Matthew

AU - Sauter, Craig S.

AU - Moskowitz, Craig

AU - Nimer, Stephen D.

AU - Deangelis, Lisa M.

AU - Kaley, Thomas

AU - Grimm, Sean

AU - Louis, David N.

AU - Cairncross, J. Gregory

AU - Panageas, Katherine S.

AU - Briggs, Samuel

AU - Faivre, Geraldine

AU - Mohile, Nimish A.

AU - Mehta, Jayesh

AU - Jonsson, Philip

AU - Chakravarty, Debyani

AU - Gao, Jianjiong

AU - Schultz, Nikolaus

AU - Brennan, Cameron W.

AU - Huse, Jason T.

AU - Omuro, Antonio

N1 - Funding Information: This is an investigator-initiated prospective multicenter phase II trial sponsored by Memorial Sloan Kettering Cancer Center, supported in part by NIH grant P30 CA 008748. Schering-Plough/ Merck provided temozolomide and additional partial financial support. Publisher Copyright: © 2017 The Author(s).

PY - 2017/10/1

Y1 - 2017/10/1

N2 - Background. Anaplastic oligodendroglioma (AO) and anaplastic oligoastrocytoma (AOA) are chemotherapy-sensitive tumors with prolonged survival after radiochemotherapy. We report a prospective trial using induction temozolomide (TMZ) followed by myeloablative high-dose chemotherapy (HDC) with autologous stem-cell transplant (ASCT) as a potential strategy to defer radiotherapy. Methods. Patients with AO/AOA received 6 cycles of TMZ (200 mg/m2 × 5/28 day). Responding patients were eligible for HDC (thiotepa 250 mg/m2/day

AB - Background. Anaplastic oligodendroglioma (AO) and anaplastic oligoastrocytoma (AOA) are chemotherapy-sensitive tumors with prolonged survival after radiochemotherapy. We report a prospective trial using induction temozolomide (TMZ) followed by myeloablative high-dose chemotherapy (HDC) with autologous stem-cell transplant (ASCT) as a potential strategy to defer radiotherapy. Methods. Patients with AO/AOA received 6 cycles of TMZ (200 mg/m2 × 5/28 day). Responding patients were eligible for HDC (thiotepa 250 mg/m2/day

KW - 1p/19q codeletion

KW - Anaplastic oligodendroglioma

KW - Autologous stem cell transplant

KW - Temozolomide

UR - http://www.scopus.com/inward/record.url?scp=85030786842&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030786842&partnerID=8YFLogxK

U2 - 10.1093/neuonc/nox086

DO - 10.1093/neuonc/nox086

M3 - Article

C2 - 28472509

AN - SCOPUS:85030786842

SN - 1522-8517

VL - 19

SP - 1380

EP - 1390

JO - Neuro-Oncology

JF - Neuro-Oncology

IS - 10

ER -

Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendroglioma

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this